Storia in 2 fonti

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

The FDA has expanded approval for marstacimab-hncq, which can now be given as routine prophylaxis for all individuals aged 6 years and older with hemophilia A or B, with or without inhibitors, Pfizer announced in a press release. Marstacimab-hncq (Hympavzi, Pfizer) is the first approved nonfactor, subcutaneous prophylaxis therapy for children with hemophilia B aged 6 to 11 years.

Raccontata da

healio.com

fiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo4 g fa

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

originale

fiercepharma.com4 g fa

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

The FDA has expanded the label for Pfizer’s subcutaneous hemop | The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all…

Leggi questa versione → originale

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Confronto fonti

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

Timeline cronologica

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Confronto fonti

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

Timeline cronologica

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi